X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CADILA HEALTHCARE - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CADILA HEALTHCARE GLENMARK PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 12.0 32.4 37.0% View Chart
P/BV x 3.2 6.0 52.6% View Chart
Dividend Yield % 0.4 0.8 48.8%  

Financials

 GLENMARK PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
CADILA HEALTHCARE
Mar-17
GLENMARK PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs993460 215.9%   
Low Rs729305 239.1%   
Sales per share (Unadj.) Rs325.592.1 353.4%  
Earnings per share (Unadj.) Rs39.314.8 265.2%  
Cash flow per share (Unadj.) Rs48.718.5 263.3%  
Dividends per share (Unadj.) Rs2.003.20 62.5%  
Dividend yield (eoy) %0.20.8 27.8%  
Book value per share (Unadj.) Rs159.268.0 234.2%  
Shares outstanding (eoy) m282.171,023.74 27.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.2 63.7%   
Avg P/E ratio x21.925.8 84.9%  
P/CF ratio (eoy) x17.720.7 85.5%  
Price / Book Value ratio x5.45.6 96.1%  
Dividend payout %5.121.6 23.6%   
Avg Mkt Cap Rs m242,991391,581 62.1%   
No. of employees `00013.016.9 76.9%   
Total wages/salary Rs m16,40815,002 109.4%   
Avg. sales/employee Rs Th7,083.95,594.5 126.6%   
Avg. wages/employee Rs Th1,265.4890.1 142.2%   
Avg. net profit/employee Rs Th855.1899.9 95.0%   
INCOME DATA
Net Sales Rs m91,85794,295 97.4%  
Other income Rs m3741,286 29.1%   
Total revenues Rs m92,23095,581 96.5%   
Gross profit Rs m20,36719,036 107.0%  
Depreciation Rs m2,6443,750 70.5%   
Interest Rs m2,373450 527.4%   
Profit before tax Rs m15,72416,122 97.5%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-810-3 26,983.3%   
Tax Rs m3,8271,289 296.9%   
Profit after tax Rs m11,08815,168 73.1%  
Gross profit margin %22.220.2 109.8%  
Effective tax rate %24.38.0 304.4%   
Net profit margin %12.116.1 75.0%  
BALANCE SHEET DATA
Current assets Rs m68,74660,223 114.2%   
Current liabilities Rs m27,02753,058 50.9%   
Net working cap to sales %45.47.6 597.7%  
Current ratio x2.51.1 224.1%  
Inventory Days Days8570 121.7%  
Debtors Days Days9688 108.4%  
Net fixed assets Rs m24,13272,984 33.1%   
Share capital Rs m2821,024 27.6%   
"Free" reserves Rs m44,64368,576 65.1%   
Net worth Rs m44,92569,600 64.5%   
Long term debt Rs m45,36324,684 183.8%   
Total assets Rs m117,639152,207 77.3%  
Interest coverage x7.636.8 20.7%   
Debt to equity ratio x1.00.4 284.7%  
Sales to assets ratio x0.80.6 126.0%   
Return on assets %11.410.3 111.5%  
Return on equity %24.721.8 113.2%  
Return on capital %19.117.9 106.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15221,280 263.9%   
Fx outflow Rs m8,08410,874 74.3%   
Net fx Rs m48,06810,406 461.9%   
CASH FLOW
From Operations Rs m6,57413,495 48.7%  
From Investments Rs m-7,124-29,103 24.5%  
From Financial Activity Rs m5,43223,158 23.5%  
Net Cashflow Rs m1,9927,556 26.4%  

Share Holding

Indian Promoters % 48.3 74.8 64.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 8.3 83.1%  
FIIs % 34.4 5.9 583.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 11.0 95.5%  
Shareholders   56,727 44,069 128.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue to Fall, IT Sector Growth Projections, and Top Stocks in Action(Pre-Open)

On Wednesday, share markets in India opened in green but ended on a weak note. The BSE Sensex closed lower by 71 points to end the day at 33,704.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS